Advanced Search

 

Study ID Status Title Patient Level Data
444563/013 Completed A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa Study Listed on ClinicalStudyDataRequest.com
444563/014 Completed Reactogenicity & immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa Study Listed on ClinicalStudyDataRequest.com
444563/020 Completed Phase II, double-blind randomised, placebo controlled clinical dose-range study to assess immunogenicity and reactogenicity of an investigational vaccination regimen, and to assess immunogenicity of OPV orally co-administered to healthy infants at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
444563/021 Completed Phase II, double-blind, randomized, placebo-controlled clinical study to assess immunogenicity and reactogenicity of doses of a modified vaccine formulation versus GSK Biologicals’ live attenuated human rotavirus vaccine when orally administered to healthy infants at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
444563/022 Completed A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine Study Listed on ClinicalStudyDataRequest.com
444563/023 Completed A placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants Study Listed on ClinicalStudyDataRequest.com
444563/023(2) Completed A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-centre study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants.
444563/023(3) Completed A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants.
444563/024 Completed A multi-country & multi-center study to assess the efficacy, immunogenicity & safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants Study Listed on ClinicalStudyDataRequest.com
444563/028/029/030 Completed A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants Study Listed on ClinicalStudyDataRequest.com
444563/033 Completed Study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age Study Listed on ClinicalStudyDataRequest.com
480848/005 Completed A 28 day, double blind, placebo-controlled, parallel-group dose-ranging phase IIA to examine the safety, tolerability and effects of SB-480848 on LP-PLA2 activity in dyslipidemic patients Study Listed on ClinicalStudyDataRequest.com
480848/010 Completed A multi-centre, randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of the Lp-PLA2 inhibitor SB-480848 (40, 80mg od) on carotid plaque composition in patients with carotid artery disease and planned carotid endarterectomy, stratified for statin use and gender, after 14+/-4 days treatment Study Listed on ClinicalStudyDataRequest.com
480848/012 Completed A randomized, repeat-dose, dose ranging study to evaluate the safety and pharmacokinetics of the SB480848 Enteric Coated Formulation [3A].
480848/013 Completed A Study to Evaluate the Effect of Steady-State New Chemical Entity (NCE) on the Single-Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Warfarin in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
480848/014 Completed The Effect of SB-480848 on the Pharmacokinietics of Digoxin in healthy subjects (3C)
480848/015 Completed A Study to Assess the ADME and Absolute Bioavailability of SB-480848 in healthy subjects (3C)
480848/019 Completed A Study to Assess the Effect of Steady-state Omeprazole on the Pharmacokinetics of single dose SB 480848 in Healthy Adult Subjects(3C)
480848/028 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects with Moderate Hepatic Impairment Study Listed on ClinicalStudyDataRequest.com
480848/033 Completed A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). Study Listed on ClinicalStudyDataRequest.com
480848/903 Completed A Repeat Dose, Dose Ranging Study to Evaluate the Safety and Pharmacokinetics of a Freebase Enteric Coated Formulation of SB 480848
480848/904 Completed A Study to Evaluate the Single Dose Pharmacokinetics of Enteric Coated Freebase Formulations of SB 480848 in Healthy Adults
49653/009 Completed A Multicentre, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered to Patients With Type 2 Diabetes Mellitus. Study Listed on ClinicalStudyDataRequest.com
49653/015 Completed A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Sulphonylurea therapy, When Administered to Patients with Type 2 Diabetes Mellitus. Study Listed on ClinicalStudyDataRequest.com
49653/020 Completed A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered to Patients with Type 2 Diabetes Mellitus. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.